Last reviewed 2026-04-23 · How we verify

AZD8931

AZD8931 is a PI3K inhibitor.

AZD8931 is a PI3K inhibitor. Used for Advanced solid tumours.

At a glance

Mechanism of action

AZD8931 works by inhibiting the PI3K pathway, which is involved in cell growth and survival. This can help to slow or stop the growth of cancer cells.

Approved indications

• Advanced solid tumours

Common side effects

• Diarrhoea
• Nausea
• Vomiting

Key clinical trials

• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
• SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (PHASE2)
• Phase I/II Trial of Antagonism of HER in GI Cancer (PHASE2)
• Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) (PHASE1, PHASE2)
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer (PHASE2)
• Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931 (PHASE1)
• Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (PHASE2)
• Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AZD8931 CI brief — competitive landscape report
• AZD8931 updates RSS · CI watch RSS
• AstraZeneca portfolio CI